The post SharpLink (SBET) to Commence $1.5B Stock Buyback Program appeared on BitcoinEthereumNews.com. Ether treasury firm SharpLink Gaming (SBET) has authorized a stock purchase program of up to $1.5 billion. SharpLink, which is helmed by Ethereum co-founder and ConsenSys CEO Joseph Lubin, said it will make the repurchases at a time and in amounts that depend on market conditions and share price in an announcement on Friday. “Should there exist periods where our stock trades at or below the net asset value of our ETH holdings, it would be dilutive on an ETH per share basis to issue new equity through our capital raising efforts,” co-CEO Joseph Chalom said in the announcement. “In this scenario, the accretive course of action may be to repurchase our common stock.” The Minneapolis-based company holds 740,760 ETH, worth $3.19 billion at current prices. Numerous companies have unveiled ether treasury strategies in recent months to capture the upside from generating passive yield through ETH staking. SharpLink shares traded over 10% higher at $19.85 on Friday morning following the buyback program announcement and as bitcoin surged after Fed Chair Jerome Powell’s comments opened the door to a September rate cut. Read more: Powell Puts September Rate Cut in Play; Bitcoin Pushes Higher Source: https://www.coindesk.com/markets/2025/08/22/sharplink-to-commence-usd1-5b-stock-buyback-programThe post SharpLink (SBET) to Commence $1.5B Stock Buyback Program appeared on BitcoinEthereumNews.com. Ether treasury firm SharpLink Gaming (SBET) has authorized a stock purchase program of up to $1.5 billion. SharpLink, which is helmed by Ethereum co-founder and ConsenSys CEO Joseph Lubin, said it will make the repurchases at a time and in amounts that depend on market conditions and share price in an announcement on Friday. “Should there exist periods where our stock trades at or below the net asset value of our ETH holdings, it would be dilutive on an ETH per share basis to issue new equity through our capital raising efforts,” co-CEO Joseph Chalom said in the announcement. “In this scenario, the accretive course of action may be to repurchase our common stock.” The Minneapolis-based company holds 740,760 ETH, worth $3.19 billion at current prices. Numerous companies have unveiled ether treasury strategies in recent months to capture the upside from generating passive yield through ETH staking. SharpLink shares traded over 10% higher at $19.85 on Friday morning following the buyback program announcement and as bitcoin surged after Fed Chair Jerome Powell’s comments opened the door to a September rate cut. Read more: Powell Puts September Rate Cut in Play; Bitcoin Pushes Higher Source: https://www.coindesk.com/markets/2025/08/22/sharplink-to-commence-usd1-5b-stock-buyback-program

SharpLink (SBET) to Commence $1.5B Stock Buyback Program

Ether treasury firm SharpLink Gaming (SBET) has authorized a stock purchase program of up to $1.5 billion.

SharpLink, which is helmed by Ethereum co-founder and ConsenSys CEO Joseph Lubin, said it will make the repurchases at a time and in amounts that depend on market conditions and share price in an announcement on Friday.

“Should there exist periods where our stock trades at or below the net asset value of our ETH holdings, it would be dilutive on an ETH per share basis to issue new equity through our capital raising efforts,” co-CEO Joseph Chalom said in the announcement.

“In this scenario, the accretive course of action may be to repurchase our common stock.”

The Minneapolis-based company holds 740,760 ETH, worth $3.19 billion at current prices. Numerous companies have unveiled ether treasury strategies in recent months to capture the upside from generating passive yield through ETH staking.

SharpLink shares traded over 10% higher at $19.85 on Friday morning following the buyback program announcement and as bitcoin surged after Fed Chair Jerome Powell’s comments opened the door to a September rate cut.

Read more: Powell Puts September Rate Cut in Play; Bitcoin Pushes Higher

Source: https://www.coindesk.com/markets/2025/08/22/sharplink-to-commence-usd1-5b-stock-buyback-program

Market Opportunity
PlaysOut Logo
PlaysOut Price(PLAY)
$0.02204
$0.02204$0.02204
+4.75%
USD
PlaysOut (PLAY) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03